These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407 [TBL] [Abstract][Full Text] [Related]
6. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175 [TBL] [Abstract][Full Text] [Related]
8. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407 [TBL] [Abstract][Full Text] [Related]
9. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840 [TBL] [Abstract][Full Text] [Related]
10. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623 [TBL] [Abstract][Full Text] [Related]
11. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
12. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Mavaddat N; Barrowdale D; Andrulis IL; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Spurdle A; Robson M; Sherman M; Mulligan AM; Couch FJ; Engel C; McGuffog L; Healey S; Sinilnikova OM; Southey MC; Terry MB; Goldgar D; O'Malley F; John EM; Janavicius R; Tihomirova L; Hansen TV; Nielsen FC; Osorio A; Stavropoulou A; Benítez J; Manoukian S; Peissel B; Barile M; Volorio S; Pasini B; Dolcetti R; Putignano AL; Ottini L; Radice P; Hamann U; Rashid MU; Hogervorst FB; Kriege M; van der Luijt RB; ; Peock S; Frost D; Evans DG; Brewer C; Walker L; Rogers MT; Side LE; Houghton C; ; Weaver J; Godwin AK; Schmutzler RK; Wappenschmidt B; Meindl A; Kast K; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Varon-Mateeva R; Schönbuchner I; Gevensleben H; Stoppa-Lyonnet D; Belotti M; Barjhoux L; ; Isaacs C; Peshkin BN; Caldes T; de la Hoya M; Cañadas C; Heikkinen T; Heikkilä P; Aittomäki K; Blanco I; Lazaro C; Brunet J; Agnarsson BA; Arason A; Barkardottir RB; Dumont M; Simard J; Montagna M; Agata S; D'Andrea E; Yan M; Fox S; ; Rebbeck TR; Rubinstein W; Tung N; Garber JE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet MM; Singer CF; Tea MK; Rappaport C; Mai PL; Greene MH; Sokolenko A; Imyanitov E; Toland AE; Senter L; Sweet K; Thomassen M; Gerdes AM; Kruse T; Caligo M; Aretini P; Rantala J; von Wachenfeld A; Henriksson K; ; Steele L; Neuhausen SL; Nussbaum R; Beattie M; Odunsi K; Sucheston L; Gayther SA; Nathanson K; Gross J; Walsh C; Karlan B; Chenevix-Trench G; Easton DF; Antoniou AC; Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):134-47. PubMed ID: 22144499 [TBL] [Abstract][Full Text] [Related]
13. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459 [TBL] [Abstract][Full Text] [Related]
14. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589 [TBL] [Abstract][Full Text] [Related]
15. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis. Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107 [TBL] [Abstract][Full Text] [Related]
16. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis. Tas F Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195 [TBL] [Abstract][Full Text] [Related]
18. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428 [TBL] [Abstract][Full Text] [Related]
19. PML protein expression in hereditary and sporadic breast cancer. Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia? Khabaz MN Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]